

PRESS RELEASE

Mid-States PLC

("Mid-States" or the "Company")

Hospital reports AD responsible for major reduction in *C.diff* cases.

Acute ward approaches or exceeds sterility of operating theatres.

Mid-States PLC announces that Sunderland Royal Hospital has reported significant reductions in *Clostridium difficile* (*C.diff*) infections in wards where the Company's Air Disinfection technology is in use.

Mr Leslie Boobis, the Medical Director of the hospital, has concluded a preliminary analysis on the number of patient infections in wards where the AD units have been installed compared with an identical ward where the units have not been in use.

Although the hospital has adopted a range of important initiatives in their successful battle to reduce hospital acquired infections, the effects of the AD are very marked. Most importantly, a ward with the unit in operation has identified only 3 instances of *C.diff** compared with an incidence of 16 in an identical ward without the machine. The previous year, the ward now fitted with the AD had 31 instances.

Mr Boobis said: "We are very pleased with the results we have seen in the patient wards where the Air Disinfection technology has been deployed. *C.diff* is a highly contagious and potentially life-threatening condition and, through improving the air quality, and our continued vigilance with cleanliness, we appear to be achieving real reductions in our infection rates."

Dr Chris Settle, Consultant Microbiologist and Infection Control Doctor, commented:

"Inov8 AD devices were employed in an infection control ward and two care of the elderly wards from the beginning of 2008. Monitoring of airborne micro-organisms was carried out on a weekly basis, using almost the same method as that employed to test air quality in operating theatres.

Air quality in a working ward with a number of sick patients (with infections such as *C.diff*) would not be expected to compare with the sterile conditions of an operating theatre.

Over a six month period, for 95% of the time, the results in the *C.diff* ward were better than the acceptable level for a working operating theatre. In 13% of the tests a count below (better than) that required for an empty operating theatre was obtained.

This is extremely impressive and certainly suggests that the AD devices are significantly reducing airborne micro-organisms."

David Macdonald, Chief Science Officer of Mid-States PLC and the developer of the technology, said:

“The experience in Sunderland Royal Hospital, and in other hospitals, confirms that in the clinical environment of a hospital, the AD delivers major patient benefits. This experience also confirms the results obtained over years of experimentation in laboratories at Porton Down and Leeds University. The fact that the AD has only beneficial effects even with critically ill patients further validates the use of the devices not just in the broad spectrum of healthcare facilities but also in domestic and commercial premises to provide critical protection against infection.”

Andrew Tonks, Finance Director of Mid-States PLC said:

“The very real clinical benefits of the technology should not obscure the financial payback. Saving one patient from a serious hospital acquired infection has a cost benefit many times the price of the devices. The effect of the AD in reducing hospital acquired infections releases hospital beds improving the service to patients generally.”

Mike Heath, Managing Director of Mid-States PLC said:

“These results make a compelling case for our technology and support the roll-out of the AD in multiple countries through carefully selected distributors and our own growing direct sales effort.”

*Note: some *C.diff* infections occur spontaneously following antibiotic regimes: the key reduction is in cross infections. A similar experience with noro-virus where cross infections appear to have been eliminated is reported by another hospital using the AD.

For further information:

Mid-States PLC

Andrew J Tonks, Finance Director
Tony Hunter, Company Secretary

Tel: +44 (0) 20 7603 1515